UTHEVER® NMN has completed the EU Novel Food public consultation phase and moved into EFSA’s risk assessment stage, marking an important step toward potential EU market compliance. While final authorization remains subject to official publication and EU decision-making, this progress gives supplement brands, distributors, and retailers a valuable opportunity to prepare product formulations, compliance wording, documentation, and European channel strategies in advance.

As the healthy-aging market surges, ingredients like NMN and NAD+ are gaining global attention—but regulatory barriers in the UK and EU are rising just as fast. This article breaks down the complex landscape of novel food compliance, revealing why approval is no longer just a regulatory step, but a strategic advantage. From EFSA requirements to evolving FSA pathways, discover how scientific validation, manufacturing precision, and early compliance planning can determine market success. For companies navigating the future of longevity innovation, understanding novel food regulation is not optional—it’s the key to unlocking opportunity.